^
    1d
    SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
    P2, N=818, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 overexpression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    1d
    CD70-targeted immunoPET Imaging of Malignant Cancers (clinicaltrials.gov)
    P2, N=300, Recruiting, RenJi Hospital | Phase classification: P=N/A --> P2
    Phase classification
    |
    CD70 (CD70 Molecule)
    2d
    Molecular Functions and Drug Prediction of MMP1 and TGFBR2 in Nasopharyngeal Carcinoma. (PubMed, J Clin Lab Anal)
    MMP1 and TGFBR2 were identified as EMT-related biomarkers that mediated immune evasion and metastasis in NPC. Dexamethasone may target these genes, offering a novel therapeutic strategy for NPC.
    Journal
    |
    TGFBR2 (Transforming Growth Factor Beta Receptor 2) • ITK (IL2 Inducible T Cell Kinase) • MMP1 (Matrix metallopeptidase 1)
    |
    dexamethasone
    2d
    Structural patterns and transcriptional effects of integrated Epstein-Barr Virus revealed by long-read sequencing and RNA-sequencing in nasopharyngeal carcinoma. (PubMed, Virol J)
    Notably, EBV-human fusion events were prevalent in EBV-associated NPCs, including intriguing fusion transcripts such as LRRC8C-RPMS1 and LINC00486-RPMS1, which provide further evidence of the oncogenic potential of EBV integration. Taken together, this study uncovers EBV integration patterns in Nasopharyngeal carcinogenesis using long-read sequencing technology.
    Journal
    |
    ZMYM2 (Zinc Finger MYM-Type Containing 2) • CD96 (CD96 Molecule) • ASH1L (ASH1 Like Histone Lysine Methyltransferase)
    2d
    Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=474, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting
    Enrollment closed • Head-to-Head
    2d
    Photon Intensity-modulated Radiotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P=N/A, N=504, Not yet recruiting, Guangzhou Concord Cancer Center
    New trial
    2d
    SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=148, Recruiting, Sun Yat-sen University | Trial completion date: Jul 2028 --> Dec 2028 | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • Loqtorzi (toripalimab-tpzi)
    3d
    Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition (clinicaltrials.gov)
    P3, N=266, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2024 --> Dec 2029 | Trial primary completion date: Jul 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin
    3d
    Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    cisplatin
    3d
    EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P1/2, N=148, Recruiting, Sun Yat-sen University | Trial completion date: Feb 2029 --> Jun 2029 | Trial primary completion date: Feb 2027 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine
    3d
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial (clinicaltrials.gov)
    P3, N=212, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • Loqtorzi (toripalimab-tpzi)
    3d
    PPP2R2C confers radioresistance in nasopharyngeal carcinoma by suppressing ferroptosis via RPS27L stabilization. (PubMed, Cell Death Dis)
    Clinically, high PPP2R2C expression correlated with poor patient survival. These findings establish that PPP2R2C promotes NPC radioresistance by stabilizing RPS27L to inhibit ferroptosis, positioning the PPP2R2C-RPS27L axis as a novel prognostic biomarker and therapeutic target for overcoming radioresistance.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • SLC7A11 (Solute Carrier Family 7 Member 11) • PPP2R5C (Protein Phosphatase 2 Regulatory Subunit B'Gamma)